Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.47 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.39 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzene SCHEMBL27461502 | 1.00 | OPRM1 (0.47) | OPRM1SSTR4TTKHDAC1HTT | |
| SCHEMBL7683420 | 0.89 | TTK (0.46) | OPRM1SSTR4TTKHDAC1HTT | |
| SCHEMBL12906842 | 0.88 | HTT (0.49) | OPRM1SSTR4HDAC1HTTPOLB | |
| SCHEMBL6972395 | 0.86 | OPRM1 (0.50) | OPRM1SSTR4TTKHDAC1HTT | |
| Hydrochloric Acid SCHEMBL7723494 | 0.85 | OPRM1 (0.48) | OPRM1SSTR4TTKHDAC1HTT | |
| SCHEMBL9640292 | 0.84 | SSTR4 (0.54) | SSTR4HDAC1HTTPOLBAKR1C1 | |
| SCHEMBL9641250 | 0.84 | SSTR4 (0.50) | SSTR4HDAC1HTTPOLBALDH1A1 | |
| SCHEMBL6447438 | 0.83 | CYP2C19 (0.43) | OPRM1SSTR4TTKHDAC1HTT | |
| SCHEMBL2231946 | 0.83 | POLB (0.57) | OPRM1SSTR4TTKHDAC1HTR2A | |
| SCHEMBL28849376 | 0.83 | SSTR4 (0.56) | SSTR4HDAC1AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | PFIZER INC. | 2004-01-08 | — | — | US | claimed |
| EP-1192952-A2 | Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-04-03 | — | — | EP | claimed |
| CN-101230008-A | Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2008-07-30 | — | — | CN | disclosed |
| EP-1923391-A1 | Substituted heterocyclic compounds, method for preparing same and pharmaceutical compositions containing them. | sanofi-aventis (FR) | 2008-05-21 | — | — | EP | disclosed |
| CN-1295221-C | Substituted heterocyclic compounds | SANOFI AVENTIS (FR) | 2007-01-17 | — | — | CN | disclosed |
| CN-1293063-C | Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | SANOFI SYNTHELABO (FR) | 2007-01-03 | — | — | CN | disclosed |
| CN-1821241-A | Substituted heterocyclic compounds, preparation method therefor and pharmaceutical compositions containing same | SANOFI SA (FR) | 2006-08-23 | — | — | CN | disclosed |
| EP-1688416-A1 | Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them | Sanofi-Aventis (FR) | 2006-08-09 | — | — | EP | disclosed |
| CN-1636983-A | Substituted heterocyclic compounds | SANOFI AVENTIS (FR) | 2005-07-13 | — | — | CN | disclosed |
| EP-1156049-B1 | Substituted heterocyclic compounds, their process of preparation and pharmaceutical compositions containing them | SANOFI AVENTIS (FR) | 2005-06-01 | — | — | EP | disclosed |
| CN-1202093-C | Substituted heterocyclic compounds | SANOFI AVENTIS (FR) | 2005-05-18 | — | — | CN | disclosed |
| US-5977359-A | Substituted heterocyclic compounds, method of preparing them and pharmaceutical compositions in which they are present | SANOFI (FR) | 1999-11-02 | — | — | US | disclosed |
| US-5869663-A | INTERMEDIATES FOR NEUROKININ RECEPTOR ANTAGONISTS | SANOFI (FR) | 1999-02-09 | — | — | US | disclosed |
| US-5780466-A | DISORDERS ASSOCIATED WITH EXCESS TACHYKININS AND ALL NEUROKININ-DEPENDENT DISORDERS; ANALGESICS; RESPIRATORY, GASTROINTESTINAL, UROGENTIAL, IMMUNE, CARDIOVASCULAR AND CNS DISORDERS | SANOFI (FR) | 1998-07-14 | — | — | US | disclosed |
| CN-1172483-A | Substituted heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | SANOFI SA (FR) | 1998-02-04 | — | — | CN | disclosed |
| EP-0807111-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1997-11-19 | — | — | EP | disclosed |
| US-5641777-A | NEUROKININ RECEPTOR ANTAGONIST | SANOFI (FR) | 1997-06-24 | — | — | US | disclosed |
| WO-1996023787-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI (FR) | 1996-08-08 | — | — | WO | disclosed |
| CN-1053605-A | Preparation method with new replacement 4-phenyl-4-piperidyl urea of toponarcosis and analgesic effect | ASTRA AB (SE) | 1991-08-07 | — | — | CN | disclosed |
| CN-1053605-A | Preparation method with new replacement 4-phenyl-4-piperidyl urea of toponarcosis and analgesic effect | ASTRA AB (SE) | 1991-08-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006135-A1 | Combination treatment for depression and anxiety | TACR1, NPSR1, HTR3A | OPRM1 81/4885SSTR4 388/4885TTK 944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.